Pfizer Limited

NSEI:PFIZER Stock Report

Market Cap: ₹239.1b

Pfizer Valuation

Is PFIZER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFIZER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PFIZER (₹5225.65) is trading above our estimate of fair value (₹1805.88)

Significantly Below Fair Value: PFIZER is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFIZER?

Key metric: As PFIZER is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PFIZER. This is calculated by dividing PFIZER's market cap by their current earnings.
What is PFIZER's PE Ratio?
PE Ratio38.7x
Earnings₹6.18b
Market Cap₹239.06b

Price to Earnings Ratio vs Peers

How does PFIZER's PE Ratio compare to its peers?

The above table shows the PE ratio for PFIZER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average68.9x
EMCURE Emcure Pharmaceuticals
43.8x25.3%₹248.4b
CONCORDBIO Concord Biotech
64.4x26.9%₹211.3b
SUVENPHAR Suven Pharmaceuticals
135.6xn/a₹329.7b
APLLTD Alembic Pharmaceuticals
31.7x21.5%₹204.8b
PFIZER Pfizer
38.7x12.9%₹239.1b

Price-To-Earnings vs Peers: PFIZER is good value based on its Price-To-Earnings Ratio (38.7x) compared to the peer average (68.9x).

Price to Earnings Ratio vs Industry

How does PFIZER's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$70.43m
524652 Ind-Swift
2xn/aUS$13.12m
No more companies available in this PE range
PFIZER 38.7xIndustry Avg. 31.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PFIZER is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is PFIZER's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFIZER PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.7x
Fair PE Ratio37x

Price-To-Earnings vs Fair Ratio: PFIZER is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the estimated Fair Price-To-Earnings Ratio (37x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PFIZER forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹5,225.65
₹5,935.00
+13.6%
14.8%₹7,175.00₹5,300.00n/a3
Nov ’25₹5,159.40
₹5,935.00
+15.0%
14.8%₹7,175.00₹5,300.00n/a3
Oct ’25₹5,562.50
₹5,935.00
+6.7%
14.8%₹7,175.00₹5,300.00n/a3
Sep ’25₹6,065.05
₹5,935.00
-2.1%
14.8%₹7,175.00₹5,300.00n/a3
Aug ’25₹5,640.35
₹5,476.67
-2.9%
4.2%₹5,800.00₹5,300.00n/a3
Jul ’25₹4,602.30
₹4,975.00
+8.1%
6.0%₹5,330.00₹4,595.00n/a3
Jun ’25₹4,609.75
₹4,953.33
+7.5%
6.1%₹5,330.00₹4,595.00n/a3
May ’25₹4,257.20
₹4,720.33
+10.9%
8.0%₹5,036.00₹4,190.00n/a3
Apr ’25₹4,448.35
₹4,720.33
+6.1%
8.0%₹5,036.00₹4,190.00n/a3
Mar ’25₹4,589.95
₹4,720.33
+2.8%
8.0%₹5,036.00₹4,190.00n/a3
Feb ’25₹4,578.20
₹4,526.33
-1.1%
7.5%₹4,954.00₹4,125.00n/a3
Jan ’25₹4,267.50
₹4,352.25
+2.0%
9.7%₹4,954.00₹3,830.00n/a4
Dec ’24₹4,101.40
₹4,441.80
+8.3%
9.4%₹4,954.00₹3,830.00n/a5
Nov ’24₹3,883.25
₹4,441.80
+14.4%
9.4%₹4,954.00₹3,830.00₹5,159.405
Oct ’24₹3,859.65
₹4,441.80
+15.1%
9.4%₹4,954.00₹3,830.00₹5,562.505
Sep ’24₹3,815.55
₹4,441.80
+16.4%
9.4%₹4,954.00₹3,830.00₹6,065.055
Aug ’24₹4,023.50
₹4,460.00
+10.8%
8.6%₹4,800.00₹3,830.00₹5,640.355
Jul ’24₹3,777.15
₹4,460.00
+18.1%
8.6%₹4,800.00₹3,830.00₹4,602.305
Jun ’24₹3,810.25
₹4,595.00
+20.6%
4.9%₹4,800.00₹4,200.00₹4,609.755
May ’24₹3,751.65
₹4,988.40
+33.0%
8.3%₹5,500.00₹4,505.00₹4,257.205
Apr ’24₹3,467.15
₹4,988.40
+43.9%
8.3%₹5,500.00₹4,505.00₹4,448.355
Mar ’24₹3,811.20
₹4,988.40
+30.9%
8.3%₹5,500.00₹4,505.00₹4,589.955
Feb ’24₹3,821.15
₹5,179.40
+35.5%
6.9%₹5,500.00₹4,505.00₹4,578.205
Jan ’24₹4,431.70
₹5,297.40
+19.5%
8.2%₹5,790.00₹4,505.00₹4,267.505
Dec ’23₹4,550.35
₹5,297.40
+16.4%
8.2%₹5,790.00₹4,505.00₹4,101.405
Nov ’23₹4,395.65
₹5,225.40
+18.9%
7.5%₹5,550.00₹4,480.00₹3,883.255

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

7D

-1.7%

1Y

15.6%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Colinz Laboratories

₹138.6m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹55.02

7D

-8.8%

1Y

33.1%